Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 2/20 | 0.32 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.32 |
| ▸ | MME | P08473 | 1/20 | 0.32 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.32 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.31 |
| ▸ | NPY4R | P50391 | 2/20 | 0.31 |
| ▸ | NPY1R | P25929 | 1/20 | 0.31 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.31 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25488443 | 0.97 | NPY4R (0.35) | ANPEPRNPEPMMEDNPEPERAP2 | |
| SCHEMBL20468520 | 0.88 | L3MBTL1 (0.39) | ANPEPRNPEPMMEDNPEPERAP2 | |
| SCHEMBL20465427 | 0.88 | CTSL (0.32) | ANPEPRNPEPDNPEPERAP2SCN9A | |
| SCHEMBL18451208 | 0.88 | CTSL (0.32) | ANPEPRNPEPDNPEPERAP2SCN9A | |
| SCHEMBL18476683 | 0.87 | MME (0.34) | ANPEPRNPEPMMEDNPEPERAP2 | |
| SCHEMBL26946628 | 0.87 | MME (0.34) | ANPEPRNPEPMMEDNPEPERAP2 | |
| SCHEMBL25487396 | 0.85 | FOLH1 (0.43) | ANPEPRNPEPMMEDNPEPERAP2 | |
| SCHEMBL25760775 | 0.85 | L3MBTL1 (0.37) | NPY4RNPY1RBIRC2 | |
| SCHEMBL20465433 | 0.85 | CTSB (0.37) | ANPEPRNPEPDNPEPERAP2NPY4R | |
| SCHEMBL18478758 | 0.84 | ERAP2 (0.33) | ANPEPRNPEPMMEDNPEPERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11759444-B2 | Methods for cancer and immunotherapy using prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-09-19 | — | — | US | disclosed |
| WO-2023081832-A1 | METHODS FOR PREVENTING AND TREATING ACUTE KIDNEY INJURY | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20210145779-A1 | Methods for Cancer and Immunotherapy Using Prodrugs of Glutamine Analogs | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2021-05-20 | — | — | US | disclosed |
| US-10336778-B2 | Prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180222930-A1 | PRODRUGS OF GLUTAMINE ANALOGS | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2018-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11759444-B2 | Methods for cancer and immunotherapy using prodrugs of glutamine analogs | ADORA2A, ADORA1, ADORA2B | ANPEP 1045/4885RNPEP 1387/4885MME 2643/4885 |
| US-20210145779-A1 | Methods for Cancer and Immunotherapy Using Prodrugs of Glutamine Analogs | ADORA2A, ADORA1, ADORA2B | ANPEP 1045/4885RNPEP 1387/4885MME 2643/4885 |
| US-10336778-B2 | Prodrugs of glutamine analogs | GLUL, GLS, GLS2 | ANPEP 1136/4885RNPEP 2840/4885MME 3387/4885 |
| US-20180222930-A1 | PRODRUGS OF GLUTAMINE ANALOGS | GLUL, GLS, GLS2 | ANPEP 1136/4885RNPEP 2840/4885MME 3387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.